Treatment Options for Melanoma

Learn about the latest treatments for metastatic melanoma. We’ve got it covered, from new FDA approvals to emerging approaches in immunotherapy, targeted therapy, cancer vaccines, drug combinations, antibody-drug conjugates, and more.

I’d already been leaning heavily towards a decision, and Emma helped me achieve the final decision…But Emma’s more than a scientist. She is a caring person.

Ellen
Breast cancer patient

New Melanoma Molecular Testing Options

Molecular tests help match patients to the personalized treatments that are most likely to work for them. Keep up with new developments in genetic tests, blood tests, liquid biopsies, tumor mutations, other biomarkers, precision medicine, and next-generation sequencing.

Latest Clinical Trial Results in Melanoma

Some of the most promising new treatments for metastatic melanoma are currently being tested in patients enrolled in clinical trials. We help you stay up to date on the latest results from these studies.

  • Dual Neoadjuvant Checkpoint Blockade Feasible in Melanoma

    Emma Shtivelman, PhD

    Excerpt from MedPage Today:

    “Combination neoadjuvant immune checkpoint blockade therapy yielded promising outcomes in high-risk resectable melanoma, although toxicity was an issue, according to a phase II trial.

    “The combination of ipilimumab (Yervoy) and nivolumab (Opdivo) led to improved progression-free survival (PFS), distant metastasis-free survival (DMFS), and overall survival (OS) versus neoadjuvant nivolumab monotherapy in 23 patients with high-risk resectable melanoma, reported Jennifer A. Wargo, MD, of MD Anderson Cancer Center in Houston, and colleagues in Nature Medicine.”

    Go to full article published by MedPage Today on Oct 11, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • BRAF-MEK Inhibitor Combo Extends Survival in BRAF-Mutant Melanoma

    Emma Shtivelman, PhD

    Excerpt from Cancer Network:

    “The combination of encorafenib and binimetinib resulted in longer overall survival (OS) compared with vemurafenib in patients with BRAF V600–mutant melanoma, according to results of the COLUMBUS trial. Combined with an earlier report showing improved progression-free survival (PFS), this suggests the regimen should become an important option in this setting.

    “Small-molecule BRAF inhibitors, originally introduced as monotherapy, offered improvements in outcomes for these melanoma patients. ‘However, response durations were short and BRAF inhibitor treatment was associated with the development of squamous cell skin cancer and other skin toxicities related to paradoxical MAPK pathway activation,’ wrote study authors led by Reinhard Dummer, MD, of University Hospital Zurich in Switzerland. Combinations of BRAF and MEK inhibition have improved the situation further, but better treatment options are still needed.”

    Go to full article published by Cancer Network on Sep 26, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • Could Adding a TLR9 Agonist Improve Responses in Metastatic Melanoma?

    Emma Shtivelman, PhD

    Excerpt from Cancer Network:

    “A phase I trial found promising activity and good tolerability with the combination of pembrolizumab and a stimulant of Toll-like receptor 9 (TLR9) known as SD-101 in patients with unresectable or metastatic melanoma, particularly in those who had not received prior anti–programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) therapy.

    “PD-1/PD-L1 inhibition has improved outcomes in metastatic melanoma, and studies have indicated that combination therapy can increase immune responses further. “Despite the improvement in response rates with combination immunotherapy, a large unmet need remains,” wrote study authors led by Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center.”

    Go to full article published by Cancer Network on Sep 5, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • Overall Survival Improved With Encorafenib/Binimetinib Combination in BRAF-Mutant Melanoma

    Emma Shtivelman, PhD

    Excerpt from The ASCO Post:

    In patients with advanced BRAF V600–mutant melanoma, combining the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) improved overall survival compared to vemurafenib (Zelboraf) or encorafenib as monotherapy, with a favorable toxicity profile, according to updated results from the phase III COLUMBUS trial.

    “Combined BRAF/MEK inhibitor therapy is standard of care in advanced BRAF V600–mutant melanoma, but approved combinations have unique toxicities that may impact the ability to deliver optimal treatment (ie, vemurafenib/cobimetinib [Cotellic] is associated with photosensitivity).”

    Go to full article published by The ASCO Post on Sep 10, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • Dual Immunotherapy a Winner for Melanoma Brain Mets

    Emma Shtivelman, PhD

    Excerpt from Medscape:

    “Combined immunotherapy with two checkpoint inhibitors — nivolumab (Opdivo, Bristol-Myers Squibb) and ipilimumab (Yervoy, Bristol-Myers Squibb) — has shown ‘clinically meaningful’ efficacy in patients with asymptomatic, untreated melanoma metastases to the brain, according to a report regarding new data from the CheckMate 204 open-label phase 2 study.

    ” ‘Although current practice is to start with surgery, stereotactic radiotherapy, or both followed by immunotherapy or targeted agents, our results support the initiation of immunotherapy to achieve prompt control of both extracranial and brain metastases,’ write the authors.”

    Go to full article published by Medscape on Aug 22, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • Show More
What if your doctor could know what everyone collectively knew?

Marty Tenenbaum, PhD
Founder of Cancer Commons

Living With Cancer

Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.

Patient Stories

You’re not alone. Read how other patients and caregivers navigated diagnosis, treatment, and life with cancer. We hope their stories provide insights and hope for your own cancer journey.

The Big Picture

Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.

Cancer and Covid-19

The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.